VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
IKTInhibikase Therapeutics, Inc.$1.67$119M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIKTEarnings History

IKT logoInhibikase Therapeutics, Inc. (IKT) Earnings History

Net Loss

10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$51M
● Net Loss
TTM EPS (Diluted)
$-0.52
Per share, diluted
YoY EPS Growth
+57.8%
Excellent
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-36.0%
Return on Assets-34.5%
Record Annual Net Income-$436,075FY2017
Record Quarterly EPS$-0.10Q1 2018
Consecutive Profitable Years0years
Q1 2026
Net Income-$16M
EPS (Diluted)$-0.17
YoY Growth+57.8%Excellent
QoQ Growth-28.6%Declining

Loading earnings history...

Inhibikase Therapeutics, Inc. (IKT) Earnings Overview

As of June 12, 2026, Inhibikase Therapeutics, Inc. (IKT) reported trailing twelve-month net income of -$51M, reflecting +57.8% year-over-year growth. The company earned $-0.52 per diluted share over the past four quarters.

Looking at the long-term picture, IKT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$436,075 in fiscal 2017.

Inhibikase Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including PRTA (-$151M net income, -2520.6% margin), ACAD ($376M net income, 36.5% margin), SAVA (-$106M net income), IKT has comparable earnings metrics. Compare IKT vs PRTA →

IKT Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
IKT logoIKTCurrent
-$51M$-0.52--36.0%+57.8%—
PRTA logoPRTA
-$151M$-2.79-2520.6%-63.6%-99.6%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
SAVA logoSAVA
-$106M$-2.20--17.2%+77.6%
NRXP logoNRXP
-$25M$-0.76-2336.5%-+43.9%
INVA logoINVA
$504M$5.9463.8%29.1%+816.7%
Best in group
Lowest in group

IKT Historical Earnings Data (2016–2025)

10 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$48M-75.4%-$52M$-0.49--
2024-$28M-44.6%-$29M$-1.16--
2023-$19M-5.4%-$20M$-3.57-7304.8%-7712.0%
2022-$18M-22.1%-$18M$-4.26-14625.9%-14686.2%
2021-$15M-419.2%-$15M$-4.88-476.9%-476.2%
2020-$3M+50.2%-$3M$-1.72-407.7%-403.5%
2019-$6M-165.9%-$6M$-3.34-509.7%-507.5%
2018-$2M-393.6%-$2M$-1.61-53.3%-52.5%
2017$-436,075+30.6%$-405,130$-0.25-21.2%-19.7%
2016$-628,737-$-613,288$-0.48-65.0%-63.4%

Download Data

Export IKT earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in IKT back in 2016?

Total return with dividends reinvested · 10+ years of data

Calculate Returns

How much would $100/month in IKT be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is IKT Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

IKT vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

IKT — Frequently Asked Questions

Quick answers to the most common questions about buying IKT stock.

What is IKT earnings per share (EPS)?

IKT trailing twelve-month (TTM) diluted EPS is $-0.52, reflecting +57.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.

What is Inhibikase Therapeutics, Inc.'s net income?

Inhibikase Therapeutics, Inc. (IKT) trailing twelve-month net income is $-51M as of 2025. Earnings grew +57.8% year-over-year.

Is IKT profitable?

IKT is not currently profitable on a TTM basis, reporting a net loss of $-51M. Net margin is N/A. Investors should monitor for a return to profitability.

What is IKT's earnings growth rate?

IKT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.

What are IKT's profit margins?

Inhibikase Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -36.0%.

Is IKT growing earnings?

Yes, IKT earnings are accelerating — EPS growth of +57.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-51M. Earnings momentum is strengthening.

What was IKT's best earnings year?

Inhibikase Therapeutics, Inc.'s highest annual net income on record is $-436075.00, achieved in fiscal year 2017. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.

What were IKT's earnings last quarter?

IKT's most recent reported quarter was Q1 2026. Net income was $-16M with diluted EPS of $-0.17. For a full breakdown of all quarters, see the quarterly earnings table on this page.

IKT Earnings Over Time (2016–2025)

Net income & EPS — annual and quarterly view